Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026

Detailed summary
- ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to…
- ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to ASC30 alone
- ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist designed for once-monthly to once-quarterly subcutaneous administration, demonstrates long-acting potential and robust weight loss
HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") recently presented key preclinical results for its oral small molecule GIPR agonist ASC48, GLP-1R/GIPR dual-targeted oral small molecule ASC30_48 FDC (a fixed-dose combination of ASC30 and ASC48), and a long-acting injectable GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek® 2026, being held November 14 to 17, 2026, in Washington, DC.
The two poster presentations feature in vitro activity and oral pharmacokinetics (PK) of ASC48; weight-loss data for ASC30_48 FDC; and extended PK, in vitro insulin secretion activity and weight-loss activity of ASC37.
ASC30_48 FDC is an in-house developed oral small molecule combination targeting GLP-1R and GIPR, with the potential to become a first-in-class one-pill, once-daily oral treatment for obesity and other metabolic diseases. These preclinical findings across receptor activity, oral pharmacokinetics and body weight reduction support advancing this program into further clinical development.
ASC37 was developed using Ascletis' proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. By combining agonist activity at GLP-1R, GIPR and GCGR with a long-acting PK profile, ASC37 is designed to offer a potential once-monthly to once-quarterly subcutaneous treatment for chronic weight management, with an injection volume of no more than 1 mL.
1. Greater Weight Reduction Observed with ASC30_48 FDC than with ASC30 Monotherapy in NHPs
In a randomized study, 15 male cynomolgus monkeys were allocated to…
Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)
